Mario Balsa: When it comes to 5-FU, less might just be more for the marrow
Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology (ICO), shared a post on X:
“New meta-analysis explores skipping 5-FU bolus in GI cancer chemo (7 studies | 12,698 pts).
No OS (HR 0.96) or PFS (HR 0.94) difference. Less toxicity without bolus:
- G3–4 neutropenia (OR 0.46)
- Thrombocytopenia (OR 0.53)
When it comes to 5-FU, less might just be more for the marrow. Congrats to Yakup Ergün and all the team.”
Title: Efficacy and safety of omitting 5-fluorouracil bolus in combination chemotherapy regimens for gastrointestinal cancers: a systematic review and meta-analysis
Authors: Yusuf Ilhan, Onur Yazdan Balcık, Elif Sahın, Aysegul Merc Cetınkaya, Elvina Almuradova, Murat Bardakcı, Cigdem Dınckal, Murat Karateke, Kadriye Bır Yucel, Arif Hakan Onder, Yakup Ergun
Read the Full Article.
More posts featuring Mario Balsa.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023